Canaccord Genuity Group Cuts Niagen Bioscience (NASDAQ:NAGE) Price Target to $13.00

Niagen Bioscience (NASDAQ:NAGE) had its target price decreased by stock analysts at Canaccord Genuity Group from $14.00 to $13.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target would suggest a potential upside of 154.90% from the company’s previous close.

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Niagen Bioscience Stock Performance

Shares of NASDAQ NAGE traded up $0.16 during trading on Thursday, reaching $5.10. The stock had a trading volume of 4,447,699 shares, compared to its average volume of 1,110,155. Niagen Bioscience has a one year low of $4.72 and a one year high of $14.69. The firm’s 50 day moving average price is $5.80 and its two-hundred day moving average price is $7.19. The stock has a market cap of $407.01 million, a PE ratio of 21.25 and a beta of 2.11.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Invesco Ltd. raised its stake in Niagen Bioscience by 28.5% during the 4th quarter. Invesco Ltd. now owns 43,641 shares of the company’s stock valued at $278,000 after purchasing an additional 9,688 shares during the period. Corient Private Wealth LLC purchased a new stake in shares of Niagen Bioscience during the 4th quarter worth about $204,000. SummitTX Capital L.P. bought a new position in Niagen Bioscience during the fourth quarter valued at approximately $79,000. Tudor Investment Corp ET AL bought a new stake in Niagen Bioscience in the fourth quarter worth $360,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Niagen Bioscience during the 4th quarter worth about $104,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Niagen Bioscience

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Q4 and FY results beat expectations — Q4 revenue came in at ~$33.8M with EPS above consensus ($0.05 vs. ~$0.02 estimate); full‑year 2025 net sales were $129.4M and net income rose to $17.4M (FY growth +103%). These beats and the solid Tru Niagen retail growth helped drive investor optimism. Niagen FY2025 Results
• Positive Sentiment: Margin and profitability signals — Gross margin expanded to ~64.1% and management reiterated profitable growth metrics; upbeat earnings commentary and the beats prompted large intraday/after‑hours rallies in some sessions. Q4 Market Reaction
• Neutral Sentiment: Management commentary and call transcripts available — Earnings call transcripts and analyst writeups detail drivers (Tru Niagen retail strength, marketing and international execution) but contain mixed forward commentary; these provide context for the guidance and valuation discussion. Earnings Call Transcript
• Neutral Sentiment: Analyst/valuation pieces weighing the guidance — Commentary is parsing FY26 growth targets and multiples; some analysts updated models after management provided “double‑digit” sales guidance. Valuation After Guidance
• Negative Sentiment: FY2026 revenue guidance came in below consensus — management’s 2026 revenue range (~$142.4M–$148.8M) is below the street (~$153M), which could cap upside and explains some mixed intraday reactions despite the beat.
• Negative Sentiment: Q4 net income nuance — Q4 net income was lower versus the prior‑year quarter ($4.1M vs. $7.2M) because Q4 2024 included a one‑time benefit; investors should note the quarter‑to‑quarter noise when modeling margins. Q4 Details

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.